The published review examines dopamine’s role in tic generation and how approved and investigational drugs may affect dopamine to reduce tics as well as synthesizes clinical trial evidence that ...
Based on a post hoc analysis, a majority of participants (~70%) experienced clinically meaningful tic reduction within 8 weeks of starting ecopipam An interim 18-month analysis of an ongoing ...
INCHEON, Korea & TEL AVIV, Israel--(BUSINESS WIRE)-- Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the companies have entered into a ...
TEL AVIV, Israel, Sept. 30, 2026 (GLOBE NEWSWIRE) -- TAPI (Technology & API Services) today announced the appointment of Serge Rogasik as its Chief Executive Officer. Mr. Rogasik will lead a global ...
TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third ...
TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2026 Aide Memoire is available on the ...
New data revealed that healthcare providers prioritize drowsiness risk, duration of available data demonstrating long-term response and drug-drug interaction profile when selecting a treatment for ...
New findings show favorable treatment continuity for UZEDY compared to other long-acting injectables in schizophrenia, as well as oral antipsychotics in bipolar I disorder (BD-I) The new real-world ...
In a post hoc analysis of the open-label safety stage of the Phase 3 SOLARIS trial, more than half of participants receiving TEV-'749 achieved stabilization, few relapsed and more than one-fifth of ...
Long-acting injectables (LAIs) offer an opportunity to improve adherence and potential outcomes for patients with schizophrenia LongActingImpact.com is a new resource center designed to support ...
PARSIPPANY, N.J. and TEL AVIV, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), a global biopharmaceutical company, today announced that its ...
To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results